Thursday, October 30, 2014 Last update: 8:33 AM - Covering Large & Obscure Tech Companies Since 1996

Orexigen Therapeutics to Present at the Wells Fargo Securities 2014 Healthcare Conference

Companies mentioned in this article: Orexigen Therapeutics, Inc.

SAN DIEGO, June 13, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will present a company overview at the Wells Fargo Securities 2014 Healthcare Conference in Boston. The presentation is scheduled for Wednesday, June 18(th) at 1:50 p.m. EDT. To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the Company's Web site at A replay will be available for 14 days after the event.

About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is NB32. Based on successful results of the Light Study, an ongoing cardiovascular outcomes trial, Orexigen's strategy for NB32 is to pursue approvals worldwide and pharmaceutical partnerships for global commercialization. The Company has submitted applications for marketing authorization in the United States and Europe, with potential approvals in 2014. If approved, North American partner Takeda Pharmaceuticals will commercialize NB32 in the United States. The Company's other product candidate, Empatic(TM), has completed Phase 2 clinical trials. Further information about the Company can be found at

    Orexigen Contact:                          Media Contact:

    McDavid Stilwell                           Denise Powell

    VP, Corporate Communications and
     Business Development                      BrewLife

    (858) 875-8629                             (510) 703-9491

SOURCE Orexigen Therapeutics, Inc.